IntriCon Corporation (NASDAQ:IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced financial results for its first quarter ended March 31, 2015.
First-Quarter Highlights:
- Net sales of $16.6 million and EPS of $0.05 were in line with expectations;
- The company’s Medtronic business rose 29 percent sequentially;
- IntriCon generated $1.2 million of cash from operating activities, a 27 percent increase year over year;
- The company made significant progress advancing its technology portfolio and required infrastructure to support IntriCon’s value hearing health initiatives; and,
- The company amended its credit facilities with The PrivateBank, creating a lending structure with broader financial flexibility.
Financial Results
For the 2015 first quarter, the company
reported net sales of $16.6 million, compared to $17.3 million in the
prior-year period. IntriCon posted net income of $284,000, or $0.05 per
diluted share, versus net income of $517,000, or $0.09 per diluted
share, for the 2014 first quarter. Included in 2014 first-quarter
results was a net loss from discontinued operations of $270,000, or
$0.05 per diluted share.
“We are pleased with our first-quarter performance, with revenue and profitability in line with our previously stated expectations,” said Mark S. Gorder, president and chief executive officer of IntriCon. “In addition to the anticipated sequential increase in our Medtronic business, we also continued to build the infrastructure required to secure high-potential opportunities in value hearing health and medical biotelemetry markets.”
Gross profit margins were 26.1 percent compared to 27.6 percent in the prior-year first quarter. The decrease was primarily due to lower overall sales volumes partially offset by a more favorable product mix.
Business Update
Hearing health sales declined 5 percent
during the first quarter from the prior-year quarter, primarily due to
decreases in the conventional hearing health channel, partially offset
by gains in targeted value hearing health initiatives, including value
hearing aids, personal sound amplifier products (PSAP) and assistive
listening devices.
Said Gorder, “We continue to make strides in the value hearing health market. Through our partnership with PC Werth, we anticipate having product approved and available for sale to the National Health Service (NHS) during the second quarter. The NHS is widely seen as the most efficient hearing aid delivery system in the world, supplying an estimated 1.4 million hearing aids annually. We believe we are well positioned to serve their needs, and we’re developing new technologies to further enhance delivery efficiencies and product standards in the future.
“In addition to the NHS, we anticipate securing other notable partners in the value hearing health market, as industry growth within the conventional channel continues to stagnate due to high device costs, distribution inefficiencies, retail consolidation and market share growth from big box retailers. These factors, along with the rapidly growing aging population, have created a need for the outcomes-based hearing health model we offer.”
Sales in IntriCon’s medical business declined 6 percent in the 2015 first quarter, primarily driven by an anticipated reduction in sales to IntriCon’s largest customer, Medtronic. To support Medtronic’s MiniMed 530G insulin pump launch in late 2013, IntriCon built and sold significant inventory from the fourth quarter of 2013 through the first half of 2014. While Medtronic volumes were down year over year, the company experienced double-digit sequential revenue growth of 29 percent from the 2014 fourth quarter. IntriCon anticipates sequential Medtronic revenue gains throughout 2015.
First-quarter 2015 professional audio communication sales rose 6 percent from the prior-year period. IntriCon will continue to leverage its core technologies in professional audio communication to support existing customers, as well as seek related hearing health and medical product opportunities.
During the 2015 first quarter, IntriCon amended its credit facilities with The PrivateBank. The amendment includes, among other things: an increase in IntriCon’s term loan to $5.0 million from a current balance of $1.75 million; an extension of the term loan and revolving loan maturity date to February 28, 2019; an increase in the annual capital expenditure limit to $4.5 million; and the implementation of investment provisions allowing for up to $4.0 million in investment spending prior to requiring bank approval.
Said Gorder, “The amendment with The PrivateBank provides the financial flexibility to support value hearing health and medical biotelemetry growth initiatives and related core technology development. We are currently evaluating a number of opportunities.”
Looking Ahead
Concluded Gorder, “I am encouraged with the
positive start to the year. Financially, we intend to build on our
momentum, and anticipate sequential revenue growth in the second-quarter
and higher sales for the full year. Strategically, we remain focused on
our stated goals of aggressively extending our value hearing health
reach and pursuing opportunities within the medical biotelemetry market.
We have made great strides advancing our technology portfolio, building
our value hearing health infrastructure and securing key channel
partners. As the year progresses, we anticipate announcing additional
key milestones that will fuel long-term growth.”
Conference Call Today
As previously announced, the company
will hold an investment community conference call today, Thursday, April
23, 2015, beginning at 4 p.m. CT. Mark Gorder, president and chief
executive officer, and Scott Longval, chief financial officer, will
review first-quarter performance and discuss the company’s strategies.
To join the conference call, dial: 1-888-428-9480 and provide the
conference ID number 5858575 to the operator.
A replay of the conference call will be available three hours after the call ends through 6:00 p.m. CT on Thursday, May 7, 2015. To access the replay, dial 1-888-203-1112 and enter passcode: 5858575.
About IntriCon Corporation
Headquartered in Arden Hills,
Minn., IntriCon Corporation designs, develops and manufactures miniature
and micro-miniature body-worn devices. These advanced products help
medical, healthcare and professional communications companies meet the
rising demand for smaller, more intelligent and better connected
devices. IntriCon has facilities in the United States, Asia and Europe.
The company’s common stock trades under the symbol “IIN” on the NASDAQ
Global Market. For more information about IntriCon, visit www.intricon.com.
Forward-Looking Statements
Statements made in this release
and in IntriCon’s other public filings and releases that are not
historical facts or that include forward-looking terminology are
“forward-looking statements” within the meaning of the Securities
Exchange Act of 1934, as amended. These forward-looking statements may
be affected by known and unknown risks, uncertainties and other factors
that are beyond IntriCon’s control, and may cause IntriCon’s actual
results, performance or achievements to differ materially from the
results, performance and achievements expressed or implied in the
forward-looking statements. These risks, uncertainties and other factors
are detailed from time to time in the company’s filings with the
Securities and Exchange Commission, including the Annual Report on Form
10-K for the year ended December 31, 2014. The company disclaims any
intent or obligation to publicly update or revise any forward-looking
statements, regardless of whether new information becomes available,
future developments occur or otherwise.
| INTRICON CORPORATION | ||||||||||
| Consolidated Condensed Statements of Operations | ||||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||||
| Three Months Ended | ||||||||||
| March 31, | March 31, | |||||||||
| 2015 | 2014 | |||||||||
(Unaudited) | (Unaudited) | |||||||||
| Sales, net | $ | 16,602 | $ | 17,310 | ||||||
| Cost of sales | 12,274 | 12,537 | ||||||||
| Gross profit | 4,328 | 4,773 | ||||||||
| Operating expenses: | ||||||||||
| Sales and marketing | 987 | 1,007 | ||||||||
| General and administrative | 1,709 | 1,624 | ||||||||
| Research and development | 1,226 | 1,168 | ||||||||
| Restructuring charges | - | 83 | ||||||||
| Total operating expenses | 3,922 | 3,882 | ||||||||
| Operating income | 406 | 891 | ||||||||
| Interest expense | (103 | ) | (138 | ) | ||||||
| Other income | 136 | 60 | ||||||||
| Income from continuing operations before income taxes and discontinued operations | 439 | 813 | ||||||||
| Income tax expense | 155 | 26 | ||||||||
| Income before discontinued operations | 284 | 787 | ||||||||
| Loss on sale of discontinued operations | - | (120 | ) | |||||||
| Loss from discontinued operations, net of income taxes | - | (150 | ) | |||||||
| Net income | $ | 284 | $ | 517 | ||||||
| Basic income (loss) per share: | ||||||||||
| Continuing operations | $ | 0.05 | $ | 0.14 | ||||||
| Discontinued operations | - | (0.05 | ) | |||||||
| Net income per share: | $ | 0.05 | $ | 0.09 | ||||||
| Diluted income (loss) per share: | ||||||||||
| Continuing operations | $ | 0.05 | $ | 0.14 | ||||||
| Discontinued operations | - | (0.05 | ) | |||||||
| Net income per share: | $ | 0.05 | $ | 0.09 | ||||||
| Average shares outstanding: | ||||||||||
| Basic | 5,849 | 5,729 | ||||||||
| Diluted | 6,227 | 5,859 | ||||||||
| INTRICON CORPORATION | ||||||||||
| Consolidated Condensed Balance Sheets | ||||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||||
| March 31, | December 31, | |||||||||
2014 | 2014 | |||||||||
| (Unaudited) | ||||||||||
| Current assets: | ||||||||||
| Cash | $ | 693 | $ | 328 | ||||||
| Restricted cash | 594 | 640 | ||||||||
| Accounts receivable, less allowance for doubtful accounts of $113 at March 31, 2015 and $120 at December 31, 2014 | 7,666 | 7,673 | ||||||||
| Inventories | 9,948 | 9,983 | ||||||||
| Other current assets | 745 | 1,013 | ||||||||
| Total current assets | 19,646 | 19,637 | ||||||||
| Machinery and equipment | 35,807 | 35,104 | ||||||||
| Less: Accumulated depreciation | 31,207 | 30,859 | ||||||||
| Net machinery and equipment | 4,600 | 4,245 | ||||||||
| Goodwill | 9,194 | 9,194 | ||||||||
| Investment in partnerships | 338 | 387 | ||||||||
| Other assets, net | 443 | 498 | ||||||||
| Total assets | $ | 34,221 | $ | 33,961 | ||||||
| Current liabilities: | ||||||||||
| Checks written in excess of cash | $ | - | $ | 516 | ||||||
| Current maturities of long-term debt | 1,890 | 1,886 | ||||||||
| Accounts payable | 5,628 | 5,438 | ||||||||
| Accrued salaries, wages and commissions | 2,393 | 2,519 | ||||||||
| Deferred gain | 110 | 110 | ||||||||
| Other accrued liabilities | 1,293 | 1,364 | ||||||||
| Total current liabilities | 11,314 | 11,833 | ||||||||
| Long-term debt, less current maturities | 5,118 | 4,627 | ||||||||
| Other postretirement benefit obligations | 483 | 485 | ||||||||
| Accrued pension liabilities | 685 | 741 | ||||||||
| Deferred gain | 28 | 55 | ||||||||
| Other long-term liabilities | 102 | 113 | ||||||||
| Total liabilities | 17,730 | 17,854 | ||||||||
| Commitments and contingencies | ||||||||||
| Shareholders’ equity: | ||||||||||
| Common stock, $1.00 par value per share; 20,000 shares authorized; 5,855 and 5,844 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively | 5,855 | 5,844 | ||||||||
| Additional paid-in capital | 17,138 | 16,939 | ||||||||
| Accumulated deficit | (5,990 | ) | (6,274 | ) | ||||||
| Accumulated other comprehensive loss | (512 | ) | (402 | ) | ||||||
| Total shareholders' equity | 16,491 | 16,107 | ||||||||
| Total liabilities and shareholders’ equity | $ | 34,221 | $ | 33,961 | ||||||
Contacts:
Scott Longval, CFO, 651-604-9526
slongval@intricon.com
or
At
PadillaCRT:
Matt Sullivan, 612-455-1709
matt.sullivan@padillacrt.com
